Medicenna Therapeutics announced the issuance of U.S. Patent No. 11,680,090, titled “Interleukin-2 Fusion Proteins and Uses Thereof.” The patent further strengthens Medicenna’s intellectual property around its BiSKIT platform. The recently granted patent strengthens Medicenna’s position, expanding its Superkine toolbox to further advance its contributions to the field of cancer immunotherapy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MDNA:
- Medicenna Strengthens IP Portfolio with U.S. Patent Granted for the Use of Interleukin-2 Superkine Fusion Proteins in Oncology
- Medicenna Reports First Quarter Fiscal 2024 Financial Results and Operational Highlights
- Medicenna Therapeutics expects cash to fund operations through 3Q24
- Medicenna Therapeutics announces expected upcoming milestones
- Medicenna Therapeutics reports Q1 EPS (4c), consensus (5c)